Extensive in vivo angiogenesis following controlled release of human vascular endothelial cell growth factor: Implications for tissue engineering and wound healing

Artificial Organs

Volumn 25, Issue 7, 2001, Pages 558-565

  Elçin, Y Murat ^a,b   Dixit, Vivek ^b,c   Gitnick, Gary ^b  

^a ANKARA UNIVERSITY   (Turkey)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Angiogenesis; Calcium alginate; Controlled release; Microspheres; Tissue engineering; Vascular endothelial cell growth factor

Indexed keywords

CALCIUM; CELL ENGINEERING; CELL GROWTH; ENDOTHELIAL CELLS; GROWTH KINETICS; RATS; TISSUE; TISSUE REGENERATION;

ANGIOGENESIS; CALCIUM ALGINATE; CONTROLLED RELEASE; HUMAN VASCULAR ENDOTHELIAL CELLS; IN-VIVO; NEO-VASCULARIZATION; TISSUES ENGINEERINGS; VASCULAR ENDOTHELIAL CELL GROWTH FACTORS; VASCULARIZATION; WOUND HEALING;

MICROSPHERES;

ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; MICROSPHERE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, HUMAN; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL; ARTICLE; BIOMEDICAL ENGINEERING; COMPARATIVE STUDY; DELAYED RELEASE FORMULATION; DISEASE MODEL; DRUG EFFECT; ENZYME IMMUNOASSAY; HUMAN; IN VITRO STUDY; MALE; PHYSIOLOGY; RAT; REFERENCE VALUE; SENSITIVITY AND SPECIFICITY; TIME; WISTAR RAT; WOUND HEALING;

ANIMALS; BIOMEDICAL ENGINEERING; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; ENDOTHELIAL GROWTH FACTORS; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHOKINES; MALE; MICROSPHERES; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, WISTAR; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS; WOUND HEALING;

EID: 0035405650     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1594.2001.025007558.x     Document Type: Article

References (31)

1. Ahrendt G, Chickering DE, Ranieri JP. Angiogenic growth factors: A review for tissue engineering. Tissue Eng 1998;4: 117-30.
2. Schott RJ, Morrow LA. Growth factors and angiogenesis. Cardiovasc Res 1993;27:1155-61.
3. Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S, Epstein SE, Linger EF. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by VEGF in dogs. Circulation 1994;89:2183-9.
4. Tischer E, Mitchell R, Hartman T, Silva M, Gosporadowicz D, Fiddes JC, Abraham JA. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 1991;266: 11947-54.
5. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The VEGF family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 1991;5:1806-14.
6. Senger DR, Galli SJ, Dvorak AM, Peruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219:983-5.
7. Unemori EN, Ferrara N, Bauer EA, Amento EP. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992;153: 557-62.
8. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, Pope RM. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994;152:4149-56.
9. Clauss M, Gerlach M, Gerlach H, Brett J, Wang F, Familletti PC, Pan Y-CE, Olander JV, Connolly DT, Stern D. Vascular permeability factor: A tumor derived polypeptide that induces endothelial cell and monocyte migration. J Exp Med 1990;172:1535-45.
10. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6.
11. Yamaguchi R, Yano H, Iemura A, Ogasawa S, Haramaki M, Kojiro M. Expression of VEGF in human hepatocellular carcinoma. Hepatology 1998;28:68-77.
12. Arras M, Mollnau H, Strasser R, Wenz R, Ito WD, Schaper J, Schaper W. The delivery of angiogenic factors to heart by microsphere therapy. Nat Biotechnol 1998;16:159-62.
13. Shulman K, Rosen S, Tognazzi K, Manseau EJ, Brown LF. Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J Am Soc Nephrol 1996; 7:661-6.
14. Langer R, Moses M. Biocompatible controlled release polymers for delivery of polypeptides and growth factors. J Cell Biochem 1991;45:340-5.
15. Elçin YM, Dixit V, Gitnick G. Hepatocyte attachment on modified chitosan membranes. Oral Presentation, XXIInd Congress of European Society for Artificial Organs, ESAO, Berlin, Germany, 1995.
16. Elçin YM. Review: tissue engineering of liver. In: AA Hincal, HS Kas, eds. Biomedical Science and Technical Technology: Recent Developments in Pharmaceutical and Medical Sciences. New York: Plenum Press, 1998:109-16.
17. Elçin YM, Dixit V, Gitnick G. Hepatocyte attachment on biodegradable modified chitosan membranes: In vitro evaluation for the development of liver organoids. Artif Organs 1998;22:837-46.
18. Elçin YM, Dixit V, Lewin K, Gitnick G. Xenotransplantation of fetal porcine hepatocytes in rats using a tissue engineering approach. Artif Organs 1999;23:146-52.
19. Elçin YM, Dixit V, Gitnick G. Controlled release of endothelial cell growth factor from chitosan-albumin microspheres for localized angiogenesis: In vitro and in vivo studies. Artif Cells Blood Substit Immobil Biotechnol 1996;24:257-71.
20. Dixit V, Elçin YM, Gitnick G. Controlled release of bioactive VEGF for liver tissue engineering. Distinguished Poster Presentation, 99th Annual Meeting of the American Gastroenterological Association and the Digestive Disease Week, AGA, Orlando, FL, U.S.A., 1999.
21. Peters MC, Isenberg B, Rowley J, Mooney DJ. Release from alginate enhances the biological activity of vascular endothelial growth factor. J Biomater Sci Polym Ed 1998;9:1267-78.
22. Nimni ME. Review. Polypeptide growth factors: Targeted delivery systems. Biomaterials 1997;18:1201-25.
23. Ko C, Dixit V, Shaw W, Gitnick G. In vitro slow release profile of ECGF immobilized within calcium alginate microbeads. Artif Cells Blood Substit Immobil Biotechnol 1995; 23:143-51.
24. Lindenbaum ES, Kaufman T, Beach D, Maroudas NG. Uterine angiogenic factor induces vascularization of collagen sponges in guinea pigs. Burns 1989;15:225-9.
25. Goodwin CJ, Braden M, Downes S, Marshall NJ. Release of bioactive human growth hormone from a biodegradable material: Poly (e-caprolactone). J Biomed Mater Res 1998;40: 204-13.
26. Kenley R, Marden L, Turek T, Jin L, Ron E, Hollinger JO. Osseous regeneration in the calvarium using novel delivery systems for recombinant human bone morphogenetic protein-2. J Biomed Mater Res 1994;28:1139-47.
27. Edelman ER, Mathiowitz E, Langer R, Klagsburn M. Controlled and modulated release of basic fibroblast growth factor. Biomaterials 1991;12:619-26.
28. Elçin YM. Encapsulation of urease enzyme in xanthanalginate spheres. Biomaterials 1995;16:912-6.
29. Technical Information Sheet, AccucyteTM-Human VEGF. In vivo enzyme immunoassay for the detection of total human VEGF in complex biological fluids. CytImmune Sciences Inc., College Park, MD, U.S.A., 1998.
30. Eppley B, Elluru R, Brock C, Coleman J. The epigastric fat transfer: An alternative free flap model in the rat. Ann Plast Surg 1992;29:293-6.
31. Technical Information Sheet, VEGF (A-20) K. Immuno-CruzTM-Staining System. Santa Cruz Biotechnology Inc., Santa Cruz, CA, U.S.A., 1998.